



## **Emmes Group advances data security as ISMS certified ISO compliant**

Gold-standard accreditation underscores Emmes Group's commitment to secure and data-rich trials for biotech and pharma partners

**Rockville, Maryland** – [Emmes Group](#), a specialty, tech and AI enabled Contract Research Organization (CRO), is now accredited with ISO/IEC 27001:2022 certification following a comprehensive and rigorous audit. The data security certificate – widely seen as the gold standard for Information Security Management Systems (ISMS) – ensures that Emmes Group and its subsidiary companies; Emmes and Veridix, adhere to the highest global standards for safeguarding sensitive information across its people, processes, and technology.

The new commendation, given by International Organization for Standardization (ISO), highlights Emmes Group's ongoing commitment to providing secure, innovative, and data-driven solutions to its biotech and pharmaceutical partners. As the clinical trial industry evolves with the integration of artificial intelligence and advanced analytics, robust data security is increasingly vital to protecting trial integrity and both sensitive patient and customer data.

Commenting on the accreditation, Scott Hospes VP of Enterprise Security, Applications and Technology at Emmes Group, added: *"We are increasingly now in an age of incredibly data-rich trials, with data gathering and analysis as an integral part of accelerating development timelines and lowering trials costs. Achieving ISO/IEC 27001:2022 certification reflects our dedication to the highest standards of information security and the most up-to-date best practices. This independent verification fosters greater trust in our data handling processes and solidifies our position as a leader in the industry's transformation toward AI-driven and digital-native clinical research."*

ISO/IEC 27001:2022 provides a framework for establishing, implementing, maintaining, and continually improving an organization's ISMS. The 2022 revision introduces updated security controls designed to address modern challenges [Annex A], categorized into four domains. These controls address aspects of information security, such as access control, cryptography, physical security, and incident management – including cloud security, supply chain vulnerabilities, and emerging technologies such as AI.

By implementing these advanced controls, Emmes Group safeguards sensitive clinical trial information from breaches or unauthorized access, while aligning with global regulations, such as HIPAA and GDPR.

*Notes to editors*

### **About Emmes Group:**

Emmes Group is a privately held contract research organization (CRO), wholly owned by New Mountain Capital (<https://www.newmountaincapital.com>). The company is transforming the future



of clinical research, bringing the promise of new medical discovery closer within reach for patients. Emmes Group was founded as Emmes more than 47 years ago, becoming one of the primary clinical research providers to the US government before expanding into public-private partnerships and commercial biopharma. Today, the company is transforming the future of clinical research, by creating the industry's first specialty, tech and AI based CRO optimized to deliver programs faster, better, and more efficiently. Where human intelligence meets artificial intelligence. Learn more at [www.theemmesgroup.com](http://www.theemmesgroup.com).

**About Emmes CRO:**

Emmes CRO, founded more than 45-years ago, is a global, full-service Clinical Research Organization dedicated to the advancement of public health and biopharmaceutical innovation. Emmes CRO has supported more than 2,000 clinical trials across numerous agencies and institutes of the U.S. federal government and a wide range of biotechnology, pharmaceutical and medical device companies throughout the world. The company has built industry leading capabilities in cell and gene therapy, vaccines and infectious diseases, ophthalmology, and neuroscience. Today, we are part of the Emmes Group, helping transform the future of clinical research. Learn more at [www.emmes.com](http://www.emmes.com).

**For media enquiries, please contact:**

Dana Roche  
Director, Marketing & Communications  
[droche@emmes.com](mailto:droche@emmes.com)